Fossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil carbon use in these products is not sustainable given the current understanding of the impact of extracted, emitted, and waste carbon on our environment, climate, and vulnerable populations.
Bringing virotherapy forward
BackgroundWhether it´s oncolytic viruses or vectors for cancer therapy or modern vaccines, the demand for development, production or filling capacities is rising rapidly. To keep pace with this rise in customer demand, Vibalogics, which recently became part of the Recipharm Group, is investing around US$50m in the expansion of its Cuxhaven site by the end of the year, and even more in the US site near Boston.
Sibylla Biotech raises €23m Series A
Latest NewsVerona-based Sibylla Biotech has closed a €23m Series A financing round to advance its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) platform.
Health: still a defensive position in portfolios?
OpinionHealthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device firms and other companies across the healthcare sector benefit from steady consumer demand – still true?
AI expert XUND GmbH bags €6m seed financing
Latest NewsAustrian XUND GmbH wants to use the assets of a €6m seed financing to grow in Germany, Switzerland and Austria.
The BIOTECH Insight Newsletter presents news from biotechnology and german stock market
BackgroundIn the present newsletter special issues will be reinforced and personality of branches interviewed. Financing in sustainable production (#BRAIN_AG), synBio and AI (AIgnostics) are highlights in the Biotech Newsletter of Deutsche Börse AG.
ADC makeer Pheon Therapeutics raises $68m
Latest NewsAntibody-Drug Conjugate (ADC) specialist Pheon Therapeutics Ltd. has closed a $68m Series A financing co-led by Brandon Capital, Forbion and Atlas Venture.
Non-viral is better
BackgroundImmunogenicity and limited gene transfer capacity can negatively affect the outcome of cell and gene therapies. European Biotechnology magazine spoke to Dr Dimitrios Laurin Wagner, Berlin Center for Advanced Therapies (BeCAT) and Gene Editing for Cell Therapy group leader at Charité, on new approaches that promise to overcome some limitations of current virus-based gene therapies.
2nd European Symposium on Ultrafast Laser driven Biophotonics was a great success!
Sponsored Publications nearly 200 participants
from 23 countries
30 posters
28 talks
Biotechnology-driven carbon revolution
OpinionFossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil carbon use in these products is not sustainable given the current understanding of the impact of extracted, emitted, and waste carbon on our environment, climate, and vulnerable populations.
Kupando raises €13m to push TLR4/7 agonist
Latest NewsKupando has raised €13m in Series A financing co-led by Remiges Ventures and LifeCare Partners to initiate clinical development of KUP101.